207 related articles for article (PubMed ID: 20979573)
1. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
Dew RE; Kollins SH
Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
5. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
[TBL] [Abstract][Full Text] [Related]
6. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
Wigal SB; Raja P; Shukla A
Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
[TBL] [Abstract][Full Text] [Related]
7. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
Childress AC; Sallee FR
Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
9. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
Lopez FA; Ginsberg LD; Arnold V
Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
[TBL] [Abstract][Full Text] [Related]
10. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
11. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
Brown TE; Brams M; Gao J; Gasior M; Childress A
Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
[TBL] [Abstract][Full Text] [Related]
12. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Brams M; Giblin J; Gasior M; Gao J; Wigal T
Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
Dupaul GJ; Weyandt LL; Rossi JS; Vilardo BA; O'Dell SM; Carson KM; Verdi G; Swentosky A
J Atten Disord; 2012 Apr; 16(3):202-20. PubMed ID: 22166471
[TBL] [Abstract][Full Text] [Related]
15. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
18. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the safety of lisdexamfetamine dimesylate.
Coghill DR; Caballero B; Sorooshian S; Civil R
CNS Drugs; 2014 Jun; 28(6):497-511. PubMed ID: 24788672
[TBL] [Abstract][Full Text] [Related]
20. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
López FA; Leroux JR
Atten Defic Hyperact Disord; 2013 Sep; 5(3):249-65. PubMed ID: 23564273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
